

Publishable Summary

This quarterly report provides an overview of the project progress within the AMYPAD Prognostic and Natural History Study (WP4), with a focus on the period from January to March 2021. In Q1 2021, recruitment activity within the PNHS continues to be affected by the ongoing COVID-19 crisis. Sites are having to constantly navigate local safety measures, at times postponing visits and working with reduced visit slots. In addition, sites are still focussed on reducing the backlog of scans instead of consenting new participants into AMYPAD PNHS. However, despite these obstacles, recruitment numbers slightly improved compared to Q4 2020. Also, the total number of scans in Q1 2021 slightly improved compared to Q4 2020. Of note, in March 2021 a total of 63 PET scans were conducted which is double the usual scanning number seen in one month for AMYPAD PNHS since the beginning of the study. In total, at the end of Q1 2021, AMYPAD PNHS had 902 participants consented of which 697 have already received a PET scan. Moving forward, the Q1 of 2021 should see the approval of the global amendment (v4.0) at Tayside and sites will perform the submission of the global amendment (v5.0) to Ethics Committees and Regulatory Authorities in order for study timelines to be extended. It is expected that recruitment rates will remain the same or improve going into Q2 2021, and the number of scans per month in Q2 will follow the trend of March 2021 as it is expected that the COVID-19 measures will become more relaxed and the vaccinations will progress during Q2 2021.

For more information: info@amypad.org

Acknowledgement: This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.

